MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s2665-9913(24)00377-1

Медицинская библиотека · The Lancet. Rheumatology · 2025

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

Scherlinger Marc, Nocturne Gaetane, Radic Marko, Launay David, Richez Christophe, Bousso Philippe, Forcade Edouard, Meyer Alain, Jorgensen Christian, Bigenwald Camille, Cornec Divi, Sibilia Jean, Choquet Sylvain, Martin Thierry, Belot Alexandre, Jouret Maurine, Bitoun Samuel, Amoura Zahir, Hermine Olivier, Mariette Xavier, Donnadieu Emmanuel, Avouac Jérome, Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I)

СтатьяОбзорПеревод в очереди

Аннотация

Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.

Для цитирования: Scherlinger Marc, Nocturne Gaetane, Radic Marko, Launay David, Richez Christophe, Bousso Philippe, Forcade Edouard, Meyer Alain, Jorgensen Christian, Bigenwald Camille, Cornec Divi, Sibilia Jean, Choquet Sylvain, Martin Thierry, Belot Alexandre, Jouret Maurine, Bitoun Samuel, Amoura Zahir, Hermine Olivier, Mariette Xavier, Donnadieu Emmanuel, Avouac Jérome, Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I). CAR T-cell therapy in autoimmune diseases: where are we and where are we going?. The Lancet. Rheumatology. 2025. DOI: 10.1016/s2665-9913(24)00377-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.